Open AccessTransduction of the Macrophage Colony‐stimulating Factor Gene into Human Multidrug Resistant Cancer Cells: Enhanced Therapeutic Efficacy of Monoclonal Anti‐P‐glycoprotein Antibody in Nude Mice
Author(s) -
Sone Saburo,
Tsuruo Takashi,
Sato Shigeo,
Yano Seiji,
Nishioka Yasuhiko,
Shinohara Tsutomu
Publication year - 1996
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1996.tb00289.x
Subject(s) - monoclonal antibody , cancer research , genetic enhancement , antibody , multiple drug resistance , cancer cell , transfection , systemic administration , biology , cancer , in vivo , immunology , medicine , cell culture , drug resistance , gene , microbiology and biotechnology , biochemistry , genetics
To develop a therapeutic modality for overcoming multidrug‐resistant (MDR) cancer with anti‐MDR1 antibody, we examined the effect of macrophage colony‐stimulating factor (M‐CSF) gene transfection into MDR AD10 cells on therapy of MDR cancer with anti‐MDR1 antihody (MRK17) in nude mice. MDR human ovarian cancer (AD10) cells were transduced with the human M‐CSF gene inserted into an expression vector to establish gene‐modified cells capable of producing low (ML‐AD10), intermediate (MM‐AD10) and high (MH‐AD10) amounts of M‐CSF. Systemic administration of MRK17 resulted in significant dose‐dependent inhibition of subcutaneous growth of ML‐AD10 tumors. In contrast, systemic administration of recombinant M‐CSF in combination with MRK17 did not augment the therapeutic efficacy of MRK17 alone, but rather promoted the growth of the parent AD10 cells. To test the efficacy of in vivo M‐CSF gene therapy combined with antibody, we mixed the parent AD10 cells with MH‐AD10 cells producing a large amount of M‐CSF, and inoculated the mixed cells subcutaneously. Treatment with MRK17 inhibited growth of the mixed cells more than that of the parent cells alone. Thus, combined therapy with anti‐MDR1 mAb and M‐CSF gene modification of MDR cancer cells may provide a new immunotherapeutic modality for overcoming MDR in humans.